Elvina Almuradova/X
Jun 12, 2025, 09:15
Elvina Almuradova: A New Cohort Study Published in JAMA Oncology on Ablative Radiation for Resectable PDAC
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:
“A new cohort study published in JAMA Oncology suggests that ablative radiation therapy (A-RT) may offer a nonoperative alternative for technically resectable pancreatic ductal adenocarcinoma (PDAC) in patients with high surgical risk.
25 patients with resectable PDAC (median age 80, many with poor performance status) received A-RT (>97.5 Gy BED).
2-year outcomes:Overall survival: 43.7%
Local progression: 20.8%
No grade 4+ toxicity
Implication: A-RT could be a viable option for patients where surgery is not feasible due to age or comorbidities.”
Title: Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy
Authors: Marsha Reyngold, Joshua D. Schoenfeld, Eileen M. O’Reilly, Anna M. Varghese, Charlie White, Melissa Zinovoy, Paul B. Romesser, Abraham J. Wu, Carla Hajj, John J. Cuaron, Danny N. Khalil, Wungki Park, Wei Lu, Zhigang Zhang, Kenneth H. Yu, Luis A. Diaz Jr, Christopher H. Crane
More posts featuring Elvina Almuradova.
Abraham J Wu
Anna M. Varghese
cancer
Carla Hajj
Charlie White
Christopher H. Crane
Danny N. Khalil
Eileen M. O'Reilly
Elvina Almuradova
JAMA Oncology
John J. Cuaron
Joshua D Schoenfeld
Kenneth H Yu
Luis A. Diaz Jr
Marsha Reyngold
Melissa Zinovoy
OncoDaily
Oncology
Paul B. Romesser
Wei Lu
Wungki Park
Zhigang Zhang
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 3, 2025, 17:51
Jul 3, 2025, 17:10
Jul 3, 2025, 16:01